SHC

Analyst Note: Sotera Health Company (SHC)

Date: 2026-06-20 Subject: Structural Setup Analysis & Business Fundamentals

1. Structural Readiness

Current State: Forming Price Action: The stock is currently trading at $15.82, which is below the breakout threshold but holding above the critical support line.

• Conservative Entry: Not yet actionable (requires confirmed breakout).
• Aggressive Entry: $16.53 (Pre-breakout / Forming entry).
• Breakout Level: $19.85 (Resistance level that must be cleared to confirm the setup).
• Extension: None recorded.
• ATR Context: Current ATR is 3.2% (productive volatility).

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led. Macro Context: As of this date, there is no named secular thesis attached to SHC. The investment case is not driven by a specific macro narrative or industry-wide secular tailwind identified in the current data. Judgment Criteria: The conviction must be derived strictly from the quality of the technical setup (the forming coil) and the underlying business fundamentals (revenue growth, margin expansion, and contract visibility). Do not invent a thesis; judge the name on its structural readiness and operational execution.

3. Business Overview

Company Description: Sotera Health Company is a leading global provider of mission-critical, end-to-end sterilization solutions, laboratory testing, and advisory services for the healthcare industry. The company operates across three primary segments: Sterigenics (terminal sterilization and irradiation), Nordion (Co-60 supply and medical isotopes), and Nelson Labs (microbiological and analytical testing). Business Model: The company generates revenue through long-term, multi-year contracts servicing a global network of facilities. The model is characterized by high customer stickiness and deep integration into customer supply chains. Key Fundamentals (as of 2026-05-05):

• Revenue Growth: For the quarter ended March 31, 2026, net revenues were $280.0 million, representing a 10.0% increase year-over-year.
• Guidance (2026 Full Year): Management expects total company revenue to increase to a range of $1.23 billion to $1.25 billion, representing constant currency growth of 5% to 6.5% versus 2025.
• Segment Performance:
• Sterigenics: Expected to deliver mid- to high-single-digit constant currency revenue growth.
• Nordion: Expected to grow constant currency revenue in the low- to mid-single digits.
• Nelson Labs: Expected to see a slight return to growth in Q2, with segment income margins improving to the low- to mid-30s by year-end.
• Customer Base: Over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies are customers.
• Contract Visibility: More than 70% of revenue is supported by multi-year contracts. Specifically, 90% of Sterigenics and 90% of Nordion revenues for 2025 were from multi-year contracts. Nordion has Co-60 supply contracts extending to dates between 2026 and 2064.
• Capital Allocation: Capital expenditures for the quarter ended March 31, 2026, were $46.2 million (up from $19.9 million in the prior year). Full-year 2026 capex is guided to be in the range of $175 million to $225 million.

4. Archetype and Conviction

Archetype: Margin Inflector. Rationale: The setup fits the "Margin Inflector" archetype because the company is demonstrating a clear path to expanding profitability through operational leverage and segment mix shifts.

• Evidence: Management explicitly states that Nelson Labs margins are expected to improve throughout the year, reaching the low- to mid-30s. Combined with the guidance for adjusted EBITDA to grow at 5.5% to 7% (outpacing revenue growth of 5% to 6.5%), the company is in a phase of margin expansion.
• Conviction Stack:
• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. The earnings transcript and SEC filings provide granular, quantitative guidance on revenue, EBITDA, and segment margins.
• Setup Readiness: Partial. The 69% historical breakout rate for forming coils provides a statistical edge, but the setup is not yet confirmed.
• Rerating Potential: Dependent on the successful execution of the margin inflection and the technical breakout above $19.85.

ATR Context: The current ATR of 3.2% falls within the "productive" bucket (sub-threshold <2.5% is weak; 4-6% is the historical sweet spot). This suggests the stock has sufficient volatility to move but is not yet in the "high" or "extreme" risk zones associated with severe losers.

5. Invalidation, Strengthening, and Gaps

Invalidation:

• Fundamental: A significant miss on the 2026 revenue guidance (below $1.23B) or a failure to deliver the projected margin improvements in Nelson Labs would undermine the "Margin Inflector" thesis.

Strengthening:

• Technical: A confirmed close above $19.85 would convert the setup from "Forming" to "Confirmed-Active," validating the breakout.
• Fundamental: Confirmation of the new X-ray facility coming online and the subsequent customer conversion impacting late in the year (as mentioned in E7) would validate the growth narrative.

Gaps in Evidence:

• Valuation Multiples: No specific P/E or EV/EBITDA multiples are provided in the evidence block for 2026, making a relative valuation assessment impossible.
• Debt/Capital Structure: While capex is detailed, specific details on debt maturity schedules or interest coverage ratios are not present in the provided evidence.
• Macro Sensitivity: No explicit data on how currency fluctuations (beyond constant currency guidance) might impact the bottom line in the current environment.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Revenue guidance of $1.23B-$1.25B with 5-6.5% growth; Nelson Labs margins expected to reach low-mid 30s; 90% revenue visibility via multi-year contracts for Sterigenics and Nordion. Key risks: Technical setup remains unconfirmed (forming coil); capital expenditures rising to $175M-$225M may pressure near-term cash flow; no named secular thesis to support multiple expansion. Sizing hint: Position size should reflect the partial readiness of the forming coil; smaller than a confirmed breakout setup. Expected horizon: 3 to 6 months for the technical setup to resolve or the fundamental thesis to play out. Failure mode to watch: A daily close below $14.79 invalidating the structural support.